Anrukinzumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | IL13 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6452H9954N1714O2024S46 |
| Molar mass | 145393.34 g·mol−1 |
  (what is this?) (verify) | |
Anrukinzumab (IMA-638[1]) is a humanized monoclonal antibody designed for the treatment of asthma.[2] It targets IL-13.[3]
Anrukinzumab was developed by Wyeth.
References
[edit]- ^ "Wyeth.com | Complete Project Listing". Wyeth. 2008. Archived from the original on June 12, 2008. Retrieved November 19, 2008.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council: Anrukinzumab, American Medical Association.
- ^ Bagnasco D, Ferrando M, Varricchi G, Passalacqua G, Canonica GW (2016). "A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma". International Archives of Allergy and Immunology. 170 (2): 122–131. doi:10.1159/000447692. PMID 27637004.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |